Recombinant Human FGFR2 kinase domain His-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11812-FR

Catalog #
Availability
Size / Price
Qty
11812-FR-020
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

P21802.1

Conjugate

Unconjugated

Applications

Enzyme Activity

View all FGFR2 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human FGFR2 protein
Met459-Leu772, with a N-terminal 6-His tag

Purity

>80%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Protein identity confirmed by mass spectrometry

Predicted Molecular Mass

37 kDa

SDS-PAGE

35-39 kDa, under reducing conditions.

Activity

Measured by its ability to transfer phosphate from adenosine triphosphate (ATP) to a peptide substrate.
The specific activity is >75 pmol/min/μg, as measured under the described conditions.

Scientific Data Images for Recombinant Human FGFR2 kinase domain His-tag Protein, CF

Recombinant Human FGFR2 kinasedomain His-tag Enzyme Activity.

Recombinant Human FGFR2 kinase domain His-tag (Catalog # 11812-FR) is measured by its ability to transfer phosphate from adenosine triphosphate (ATP) to a peptide substrate.

Formulation, Preparation and Storage

11812-FR
Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, DTT and Glycerol.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: FGFR2

Fibroblast growth factor receptor 2 (FGFR2), also known as Keratinocyte growth factor receptor (KGFR), is one of four highly conserved tyrosine protein kinase FGFR receptors within the tyrosine protein kinase family that differ in ligand affinity and tissue distribution. FGFR2, like other receptor members in this family, is comprised of an extracellular domain (ECD) with immunoglobulin-like segments that binds its target cytokine FGF and heparin sulfate to induce dimerization and autophosphorylation, a single-pass transmembrane domain, and a cytosolic kinase domain that triggers downstream signaling cascades through multiple pathways (1, 2). Like the structure of other tyrosine kinases, the kinase domain contains the conserved catalytic domain with an ATP binding site within the cleft of two lobes at the N-terminal and C-terminal regions as well as an activation loop at the surface between the two lobes (3). FGFR2 has two naturally occurring isoforms, FGFR2b and FGFR2c, that are created by splicing of the third immunoglobulin-like domain and lead to tissue specific expression within epithelial and mesenchyme derived tissues respectively to bind different FGFs (4, 5). Missense mutations of FGFR2 that cause gain of function cause several congenital skeletal disorders including Apert, Crouzon, and Pfeiffer syndromes (6, 7). In addition, FGFR2 regulates signaling pathways that promote cell proliferation, inhibition of apoptosis, and angiogenesis (5). FGFR2 has been reported to be overexpressed or mutated in many tumors including brain, breast, cholangiocarcinoma, gastric, lung, ovarian and uterine, some of which have been further correlated with poor prognosis (5, 8-15). Inhibition of FGFR2 has been identified as a promising cancer therapeutic strategy and there is significant ongoing research in the development of drugs that inhibit FGFR2 using multikinase and more selective ATP-binding site small molecule and antibody drugs (2, 5, 14, 16).

References

  1. Hubbard, S.R. and J.H. Till (2000) Annu. Rev. Biochem. 69:373.
  2. Katoh, M. et al. (2024) Nature Rev. Clin. Oncol. 21:312. 
  3. Dai, S. et al. (2019) Cell. 8:614.
  4. Orr-Urtreger A. et al. (1993) Developmental Biology. 158:475.
  5. Lages Dos Santos,J. et al. (2025) Medicina 61:1890. 
  6. Pollock, P.M. et al. (2007) Oncogene 26:7158.
  7. Tuzon, C.T. et al. (2019) Curr. Osteoporos Rep. 17:138.
  8. Shoji H. et al. (2015) Anticancer Res. 35:5055.
  9. Liu, G. et al. (2017) Tumour Biol. 39:1010428317707424.
  10. Mahipal, A. et al. (2019) Cancer Treat. Rev. 78:1.
  11. Georgescu, M.M. et al. (2021) Acta Neuropathol. Commun. 9:69.
  12. Jogo, T. et al. (2021) Clin. Cancer Res. 27:5619.
  13. Pacini, L. et al. (2021) Cells 10:1154.
  14. Francavilla, C. and C.S. O'Brien (2022) Open Biol. 12:210373.
  15. Vogel, A. et al. (2023) Annu. Rev. Med. 74:293.
  16. Zingg, D. et al. (2022) Nature 608:609.

Long Name

Fibroblast Growth Factor Receptor 2

Alternate Names

CD332, FGF R2

Entrez Gene IDs

2263 (Human); 14183 (Mouse)

Gene Symbol

FGFR2

UniProt

P21802.1

Additional FGFR2 Products

Product Documents for Recombinant Human FGFR2 kinase domain His-tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human FGFR2 kinase domain His-tag Protein, CF

For research use only

Privacy Policy
Cookie Policy
Site Map
© Copyright 2026 Bio-Techne. All Rights Reserved. All trademarks and registered trademarks are the property of Bio-Techne and its brands unless otherwise specified.